These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25998298)

  • 21. Erratum. Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes. Diabetes Care 2022;45:2189-2201.
    Anderson RL; DiMeglio LA; Mander AP; Dayan CM; Linsley PS; Herold KC; Marinac M; Ahmed ST
    Diabetes Care; 2022 Dec; 45(12):3113. PubMed ID: 36219765
    [No Abstract]   [Full Text] [Related]  

  • 22. Erratum. Genetics coming of age in type 1 diabetes. Diabetes Care 2019;42:189-191.
    Cerosaletti K; Hao W; Greenbaum CJ
    Diabetes Care; 2019 May; 42(5):987. PubMed ID: 30885949
    [No Abstract]   [Full Text] [Related]  

  • 23. Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care 2019;42:2228-2236.
    Sims EK; Geyer S; Johnson SB; Libman I; Jacobsen LM; Boulware D; Rafkin LE; Matheson D; Atkinson MA; Rodriguez H; Spall M; Larsson HE; Wherrett DK; Greenbaum CJ; Krischer J; DiMeglio LA;
    Diabetes Care; 2020 Apr; 43(4):934. PubMed ID: 32132004
    [No Abstract]   [Full Text] [Related]  

  • 24. Erratum to: The new biology of diabetes.
    Pajvani UB; Accili D
    Diabetologia; 2015 Nov; 58(11):2683. PubMed ID: 26376798
    [No Abstract]   [Full Text] [Related]  

  • 25. Erratum. Amelioration of Diabetes by Protein S. Diabetes 2016;65:1940-1951.
    Yasuma T; Yano Y; D'Alessandro-Gabazza CN; Toda M; Gil-Bernabe P; Kobayashi T; Nishihama K; Hinneh JA; Mifuji-Moroka R; Roeen Z; Morser J; Cann I; Motoh I; Takei Y; Gabazza EC
    Diabetes; 2016 Dec; 65(12):3812. PubMed ID: 27803023
    [No Abstract]   [Full Text] [Related]  

  • 26. Erratum. Our National Approach to Diabetes. Diabetes Care 2023;46:252-254.
    Califf RM
    Diabetes Care; 2024 May; 47(5):899. PubMed ID: 38518072
    [No Abstract]   [Full Text] [Related]  

  • 27. Erratum to: Tumor Static Concentration Curves in Combination Therapy.
    Cardilin T; Almquist J; Jirstand M; Soselly A; Amendt C; El Bawab S; Gabrielsson J
    AAPS J; 2017 Mar; 19(2):596. PubMed ID: 28058529
    [No Abstract]   [Full Text] [Related]  

  • 28. Erratum to: Second Chance.
    Torrey EF
    Schizophr Bull; 2019 Oct; 45(6):1381. PubMed ID: 31647565
    [No Abstract]   [Full Text] [Related]  

  • 29. Erratum. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes care 2015;38:394-402.
    Lewin A; DeFronzo RA; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
    Diabetes Care; 2015 Jun; 38(6):1173. PubMed ID: 25998299
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of empagliflozin in the management of type 2 diabetes by patient profile.
    Hedrington MS; Davis SN
    Ther Clin Risk Manag; 2015; 11():739-49. PubMed ID: 25999725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
    Rosenstock J; Jelaska A; Zeller C; Kim G; Broedl UC; Woerle HJ;
    Diabetes Obes Metab; 2015 Oct; 17(10):936-48. PubMed ID: 26040302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Empagliflozin as add-on to metformin in people with Type 2 diabetes.
    Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
    Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin.
    Gallwitz B
    Ther Clin Risk Manag; 2015; 11():799-805. PubMed ID: 25999728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.
    Michel MC; Mayoux E; Vallon V
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Aug; 388(8):801-16. PubMed ID: 26108304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes.
    Ndefo UA; Anidiobi NO; Basheer E; Eaton AT
    P T; 2015 Jun; 40(6):364-8. PubMed ID: 26045645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes.
    Sjöström CD; Johansson P; Ptaszynska A; List J; Johnsson E
    Diab Vasc Dis Res; 2015 Sep; 12(5):352-8. PubMed ID: 26008804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Once-weekly exenatide as a treatment for Type 2 diabetes.
    Schauerhamer MB; Gurgle H; McAdam-Marx C
    Expert Rev Cardiovasc Ther; 2015 Jun; 13(6):611-26. PubMed ID: 26000560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.
    Fulcher G; Matthews DR; Perkovic V; de Zeeuw D; Mahaffey KW; Weiss R; Rosenstock J; Capuano G; Desai M; Shaw W; Vercruysse F; Meininger G; Neal B
    Diabetes Ther; 2015 Sep; 6(3):289-302. PubMed ID: 26081793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy.
    Gilbert RE; Krum H
    Lancet; 2015 May; 385(9982):2107-17. PubMed ID: 26009231
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.